Skip to main content
Top

25-02-2024 | Erectile Dysfunction | Urology - Original Paper

Association of METS-IR index with prevalence of erectile dysfunction in US adults: a cross-sectional study

Authors: Chao Sun, Yue Gao, Zichun Liang, Chunhui Liu, Ming Chen

Published in: International Urology and Nephrology

Login to get access

Abstract

Background

Insulin resistance (IR) is involved in the development of erectile dysfunction (ED). The purpose of this study was to assess the correlation between the metabolic score for IR (METS-IR) index and risk of erectile dysfunction in US adults.

Methods

This study selected individuals from the National Health and Nutrition Examination Survey (NHANES). Logistic regression analysis, subgroup analysis, and dose–response curve analysis were carried out to assess the relationship between the METS-IR index and ED prevalence.

Results

This study ultimately included 1759 participants aged ≥ 20 years, of whom 512 self-reported a history of ED. After adjusting for all confounders, each unit increase in METS-IR index was associated with a 3% increase in erectile dysfunction prevalence (OR = 1.03, 95% CI: 1.01–1.04). In almost all subgroups, an increased METS-IR index was associated with a higher prevalence of ED. The dose–response curve displayed a positive non-linear connection between METS-IR value and the prevalence of ED.

Conclusion

The study found a positive association between the METS-IR index and ED. METS-IR is useful as a simplified IR evaluation index for early identification of people with high risk of ED.
Literature
1.
go back to reference Patel DP, Christensen MB, Hotaling JM, Pastuszak AW (2020) Erectile dysfunction and Peyronie’s disease: genetic diseases? Eur Urol Focus 6(3):572–574CrossRefPubMed Patel DP, Christensen MB, Hotaling JM, Pastuszak AW (2020) Erectile dysfunction and Peyronie’s disease: genetic diseases? Eur Urol Focus 6(3):572–574CrossRefPubMed
2.
go back to reference Chen L, Shi GR, Huang DD et al (2019) Male sexual dysfunction: a review of literature on its pathological mechanisms, potential risk factors, and herbal drug intervention. Biomed Pharmacother 112:108585CrossRefPubMed Chen L, Shi GR, Huang DD et al (2019) Male sexual dysfunction: a review of literature on its pathological mechanisms, potential risk factors, and herbal drug intervention. Biomed Pharmacother 112:108585CrossRefPubMed
3.
go back to reference McMahon CG (2019) Current diagnosis and management of erectile dysfunction. Med J Aust 210(10):469–476CrossRefPubMed McMahon CG (2019) Current diagnosis and management of erectile dysfunction. Med J Aust 210(10):469–476CrossRefPubMed
4.
go back to reference Bello-Chavolla OY, Almeda-Valdes P, Gomez-Velasco D et al (2018) METS-IR, a novel score to evaluate insulin sensitivity, is predictive of visceral adiposity and incident type 2 diabetes. Eur J Endocrinol 178(5):533–544CrossRefPubMed Bello-Chavolla OY, Almeda-Valdes P, Gomez-Velasco D et al (2018) METS-IR, a novel score to evaluate insulin sensitivity, is predictive of visceral adiposity and incident type 2 diabetes. Eur J Endocrinol 178(5):533–544CrossRefPubMed
5.
go back to reference Nguyen HMT, Gabrielson AT, Hellstrom WJG (2017) Erectile dysfunction in young men-a review of the prevalence and risk factors. Sex Med Rev 5(4):508–520CrossRefPubMed Nguyen HMT, Gabrielson AT, Hellstrom WJG (2017) Erectile dysfunction in young men-a review of the prevalence and risk factors. Sex Med Rev 5(4):508–520CrossRefPubMed
6.
go back to reference Liu C, Gao Y, Ji J et al (2023) Association between inflammatory indexes and erectile dysfunction in U.S. adults: National Health and Nutrition Examination Survey 2001–2004. Sex Med 11(4):qfad045CrossRefPubMedPubMedCentral Liu C, Gao Y, Ji J et al (2023) Association between inflammatory indexes and erectile dysfunction in U.S. adults: National Health and Nutrition Examination Survey 2001–2004. Sex Med 11(4):qfad045CrossRefPubMedPubMedCentral
7.
go back to reference Defeudis G, Mazzilli R, Tenuta M et al (2022) Erectile dysfunction and diabetes: a melting pot of circumstances and treatments. Diabetes Metab Res Rev 38(2):e3494CrossRefPubMed Defeudis G, Mazzilli R, Tenuta M et al (2022) Erectile dysfunction and diabetes: a melting pot of circumstances and treatments. Diabetes Metab Res Rev 38(2):e3494CrossRefPubMed
8.
go back to reference Kouidrat Y, Pizzol D, Cosco T et al (2017) High prevalence of erectile dysfunction in diabetes: a systematic review and meta-analysis of 145 studies. Diabet Med 34(9):1185–1192CrossRefPubMed Kouidrat Y, Pizzol D, Cosco T et al (2017) High prevalence of erectile dysfunction in diabetes: a systematic review and meta-analysis of 145 studies. Diabet Med 34(9):1185–1192CrossRefPubMed
9.
go back to reference Maalmi H, Herder C, Bonhof GJ et al (2022) Differences in the prevalence of erectile dysfunction between novel subgroups of recent-onset diabetes. Diabetologia 65(3):552–562CrossRefPubMed Maalmi H, Herder C, Bonhof GJ et al (2022) Differences in the prevalence of erectile dysfunction between novel subgroups of recent-onset diabetes. Diabetologia 65(3):552–562CrossRefPubMed
11.
go back to reference Rivas AM, Nugent K (2021) Hyperglycemia, insulin, and insulin resistance in sepsis. Am J Med Sci 361(3):297–302CrossRefPubMed Rivas AM, Nugent K (2021) Hyperglycemia, insulin, and insulin resistance in sepsis. Am J Med Sci 361(3):297–302CrossRefPubMed
12.
go back to reference Zheng ZG, Zhu ST, Cheng HM et al (2021) Discovery of a potent SCAP degrader that ameliorates HFD-induced obesity, hyperlipidemia and insulin resistance via an autophagy-independent lysosomal pathway. Autophagy 17(7):1592–1613CrossRefPubMed Zheng ZG, Zhu ST, Cheng HM et al (2021) Discovery of a potent SCAP degrader that ameliorates HFD-induced obesity, hyperlipidemia and insulin resistance via an autophagy-independent lysosomal pathway. Autophagy 17(7):1592–1613CrossRefPubMed
13.
14.
go back to reference Beverly JK, Budoff MJ (2020) Atherosclerosis: pathophysiology of insulin resistance, hyperglycemia, hyperlipidemia, and inflammation. J Diabetes 12(2):102–104CrossRefPubMed Beverly JK, Budoff MJ (2020) Atherosclerosis: pathophysiology of insulin resistance, hyperglycemia, hyperlipidemia, and inflammation. J Diabetes 12(2):102–104CrossRefPubMed
15.
go back to reference Boccardi V, Mancinetti F, Baroni M et al (2022) Metabolic score for insulin resistance (METS-IR) and circulating cytokines in older persons: the role of gender and body mass index. Nutrients 14(15):3228CrossRefPubMedPubMedCentral Boccardi V, Mancinetti F, Baroni M et al (2022) Metabolic score for insulin resistance (METS-IR) and circulating cytokines in older persons: the role of gender and body mass index. Nutrients 14(15):3228CrossRefPubMedPubMedCentral
16.
go back to reference Behrendt D, Ganz P (2002) Endothelial function. from vascular biology to clinical applications. Am J Cardiol 90(10C):40L-48LCrossRefPubMed Behrendt D, Ganz P (2002) Endothelial function. from vascular biology to clinical applications. Am J Cardiol 90(10C):40L-48LCrossRefPubMed
17.
go back to reference Maxwell AJ (2002) Mechanisms of dysfunction of the nitric oxide pathway in vascular diseases. Nitric Oxide 6(2):101–124CrossRefPubMed Maxwell AJ (2002) Mechanisms of dysfunction of the nitric oxide pathway in vascular diseases. Nitric Oxide 6(2):101–124CrossRefPubMed
18.
go back to reference Guay AT, Traish A (2011) Testosterone deficiency and risk factors in the metabolic syndrome: implications for erectile dysfunction. Urol Clin North Am 38(2):175–183CrossRefPubMed Guay AT, Traish A (2011) Testosterone deficiency and risk factors in the metabolic syndrome: implications for erectile dysfunction. Urol Clin North Am 38(2):175–183CrossRefPubMed
19.
go back to reference Trussell JC, Legro RS (2007) Erectile dysfunction: does insulin resistance play a part? Fertil Steril 88(4):771–778CrossRefPubMed Trussell JC, Legro RS (2007) Erectile dysfunction: does insulin resistance play a part? Fertil Steril 88(4):771–778CrossRefPubMed
20.
go back to reference Russo GI, Cimino S, Fragala E et al (2014) Insulin resistance is an independent predictor of severe lower urinary tract symptoms and of erectile dysfunction: results from a cross-sectional study. J Sex Med 11(8):2074–2082CrossRefPubMed Russo GI, Cimino S, Fragala E et al (2014) Insulin resistance is an independent predictor of severe lower urinary tract symptoms and of erectile dysfunction: results from a cross-sectional study. J Sex Med 11(8):2074–2082CrossRefPubMed
21.
go back to reference Fiorentino TV, Marini MA, Succurro E et al (2019) Relationships of surrogate indexes of insulin resistance with insulin sensitivity assessed by euglycemic hyperinsulinemic clamp and subclinical vascular damage. BMJ Open Diabetes Res Care 7(1):e000911CrossRefPubMedPubMedCentral Fiorentino TV, Marini MA, Succurro E et al (2019) Relationships of surrogate indexes of insulin resistance with insulin sensitivity assessed by euglycemic hyperinsulinemic clamp and subclinical vascular damage. BMJ Open Diabetes Res Care 7(1):e000911CrossRefPubMedPubMedCentral
22.
go back to reference Carrillo-Larco RM, Miranda JJ, Gilman RH et al (2018) The HOMA-IR performance to identify new diabetes cases by degree of urbanization and altitude in Peru: the CRONICAS cohort study. J Diabetes Res 16:7434918 Carrillo-Larco RM, Miranda JJ, Gilman RH et al (2018) The HOMA-IR performance to identify new diabetes cases by degree of urbanization and altitude in Peru: the CRONICAS cohort study. J Diabetes Res 16:7434918
Metadata
Title
Association of METS-IR index with prevalence of erectile dysfunction in US adults: a cross-sectional study
Authors
Chao Sun
Yue Gao
Zichun Liang
Chunhui Liu
Ming Chen
Publication date
25-02-2024
Publisher
Springer Netherlands
Published in
International Urology and Nephrology
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-024-03961-6
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.